title: Increased expression of c-maf in pure red cell aplasia secondary to plasma cell dyscrasia.
abstract: Th2 dominancy in the peripheral T helper (Th) cell subsets were reported to be involved in the pathogenesis of pure red cell aplasia (PRCA). We encountered a PRCA case secondary to plasma cell dyscrasia that showed Th2 dominancy at the relapse of PRCA. Increased expression of c-maf, a transcriptional factor which induces Th2 differentiation of naive T-cells, and elevated expression of interleukin (IL)-4 were observed in the RNA derived from patient's bone marrow at relapse of PRCA. Following the administration of methylprednisolone which improved PRCA, normalization of Th1/Th2 ratio and decreased expression of c-maf and IL-4 were observed, which suggests that the upregulation of c-maf might have played a role in the pathogenesis of PRCA secondary to plasma cell dyscrasia.
authors.affiliation: Department of Medicine, Kagawa Prefectural Central Hospital, Takamatsu, Kagawa, Japan.
authors.forename: Yoshiko
authors.initials: Y
authors.lastname: Matsuhashi
authors.forename: Taizo
authors.initials: T
authors.lastname: Tasaka
authors.forename: Eisuke
authors.initials: E
authors.lastname: Uehara
authors.forename: Miharu
authors.initials: M
authors.lastname: Fujimoto
authors.forename: Takahiro
authors.initials: T
authors.lastname: Tamura
authors.forename: Masami
authors.initials: M
authors.lastname: Nagai
authors.forename: Toshihiko
authors.initials: T
authors.lastname: Ishida
mesh_terms: D000368:Aged; D001853:Bone Marrow / Q000378:metabolism; D002454:Cell Differentiation; D004268:DNA-Binding Proteins / Q000096:biosynthesis* / Q000235:genetics / Q000502:physiology; D005786:Gene Expression Regulation; D006801:Humans; D007145:Immunoglobulin kappa-Chains / Q000032:analysis; D007146:Immunoglobulin lambda-Chains / Q000032:analysis; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007371:Interferon-gamma / Q000096:biosynthesis / Q000235:genetics; D015847:Interleukin-4 / Q000096:biosynthesis / Q000235:genetics; D007378:Interleukins / Q000096:biosynthesis / Q000235:genetics; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use; D010265:Paraproteinemias / Q000150:complications* / Q000378:metabolism; D010266:Paraproteins / Q000032:analysis; D011518:Proto-Oncogene Proteins / Q000096:biosynthesis* / Q000235:genetics / Q000502:physiology; D051257:Proto-Oncogene Proteins c-maf; D012333:RNA, Messenger / Q000096:biosynthesis / Q000235:genetics; D012008:Recurrence; D012010:Red-Cell Aplasia, Pure / Q000188:drug therapy / Q000209:etiology / Q000378:metabolism*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D018418:Th2 Cells / Q000276:immunology; D013922:Thrombocytosis / Q000209:etiology
chemical_list: D004268:DNA-Binding Proteins; D007145:Immunoglobulin kappa-Chains; D007146:Immunoglobulin lambda-Chains; D007166:Immunosuppressive Agents; D007378:Interleukins; C495607:MAF protein, human; D010266:Paraproteins; D011518:Proto-Oncogene Proteins; D051257:Proto-Oncogene Proteins c-maf; D012333:RNA, Messenger; D015847:Interleukin-4; D007371:Interferon-gamma; D008775:Methylprednisolone